Dr. Allison C. Rosenthal, DO

Dr. Rosenthal practices at Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona.

Dr. Rosenthal's NPI, 1255568135, was assigned on June 17, 2009. Dr. Rosenthal graduated from Arizona College of Osteopathic Medicine - Glendale in 2009. Dr. Rosenthal holds Arizona license 5841.

Dr. Rosenthal's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale, at 13400 East Shea Boulevard, Scottsdale, AZ 85259. The practice phone is (480) 342-4201.

Dr. Rosenthal's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona. Dr. Rosenthal is also affiliated with Mayo Clinic Hospital - Phoenix. The medical group on file is Mayo Clinic Arizona. Dr. Rosenthal's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenthal practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosenthal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosenthal is board certified in hematology by the American Board of Internal Medicine. Dr. Rosenthal is licensed in Arizona.

Dmand AI lists anemia, chronic anemia, chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Rosenthal treats.

CMS data shows 47,028 Medicare services from Dr. Rosenthal across 46 procedure codes in 2024, for 648 Medicare patients. Medicare paid $1,195,868 for them.

CMS counts 648 Medicare patients who saw Dr. Rosenthal in 2024. The largest group is 65 to 74, with 307 patients. 73% of them have high cholesterol, and 68% have high blood pressure. 4% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenthal's median patient age at 71, with 49% women.

In 2024, Dr. Rosenthal wrote 505 Medicare Part D claims for 82 patients. 79% of them were for generic drugs. CMS names the drug for 366 of them, across 14 drugs with 11 or more claims each, at $872,764 in total drug cost. In 2023, CMS named 303 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Rosenthal for performance year 2024, reported as part of a group. Dr. Rosenthal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenthal as offering telehealth.

Dmand AI links 104 papers to Dr. Rosenthal, published from 2011 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Immunotherapy, Adoptive, Antineoplastic Combined Chemotherapy Protocols and Receptors, Chimeric Antigen. Dr. Rosenthal has published most often in Am J Hematol. Dr. Rosenthal's most frequent co-authors are Patrick Bobryk Johnston, DO, William Gary Rule, MD and Stephen M. Ansell, MD.

Dmand AI links Dr. Rosenthal to 8 clinical trials, 5 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse and Leukemia, B-Cell. Zhejiang DTRM Biopharma sponsors the most, 2.

CMS Open Payments shows 21 general payments to Dr. Rosenthal from 15 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 99% of the total. Janssen Pharmaceuticals, Inc paid the most, $337.

Dr. Rosenthal graduated from Arizona College of Osteopathic Medicine - Glendale in 2009. Dr. Rosenthal is a member of AOA.

Dr. Rosenthal is in network with 4 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross and Blue Shield of Kansas City. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.